The FDA granted approval to pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, following the KEYNOTE-689 phase 3 trial. The regimen, administered perioperatively, improved event-free survival and tumor response. This marks the first checkpoint inhibitor approved for curative-intent, perioperative use in this cancer type, representing a major treatment paradigm shift.